Andrew G Nicholson1, Kari Chansky2, John Crowley2, Ricardo Beyruti3, Kaoru Kubota4, Andrew Turrisi5, Wilfried E E Eberhardt6, Jan van Meerbeeck7, Ramón Rami-Porta8. 1. Department of Histopathology, Royal Brompton and Harefield NHS Foundation Trust and Imperial College, London, UK. Electronic address: a.nicholson@rbht.nhs.uk. 2. Cancer Research and Biostatistics, Seattle, WA, USA. 3. Department of Thoracic Surgery, University of São Paulo, São Paulo, Brazil. 4. Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan. 5. Department of Radiotherapy, Sinai Grace Hospital, Detroit, MI, USA. 6. Department of Medical Oncology, West German Cancer Centre, Ruhrlandklinik, University Hospital Essen, University Duisburg-Essen, Germany. 7. Department of Oncology, Antwerp University Hospital, Edegem (Antwerp), Belgium. 8. Department of Thoracic Surgery, Hospital Universitari Mútua Terrassa and CIBERES Lung Cancer Group, Terrassa, Barcelona, Spain.
Abstract
INTRODUCTION: Small cell lung cancer (SCLC) is commonly classified as either limited or extensive, but the Union for International Cancer Control TNM Classification of Malignant Tumours seventh edition (2009) recommended tumor, node, and metastasis (TNM) staging based on analysis of the International Association for the Study of Lung Cancer (IASLC) database. METHODS: Survival analyses were performed for clinically and pathologically staged patients presenting with SCLC from 1999 through 2010. Prognosis was compared in relation to the TNM seventh edition staging to serve as validation and analyzed in relation to proposed changes to the T descriptors found in the eighth edition. RESULTS: There were 5002 patients: 4848 patients with clinical and 582 with pathological stages. Among these, 428 had both. Survival differences were confirmed for T and N categories and maintained in relation to proposed revisions to T descriptors for seventh edition TNM categories and proposed changes in the eighth edition. There were also survival differences, notably at 12 months, in patients with brain-only single-site metastasis (SSM) compared to SSM at other sites, and SSM without a pleural effusion showed a better prognosis than other patients in the M1b category. CONCLUSION: We confirm the prognostic value of clinical and pathological TNM staging in patients with SCLC, and recommend continued usage for SCLC in relation to proposed changes to T, N, and M descriptors for NSCLC in the eighth edition. However, for M descriptors, it remains uncertain whether survival differences in patients with SSM in the brain simply reflect better treatment options rather than better survival based on anatomic extent of disease.
INTRODUCTION:Small cell lung cancer (SCLC) is commonly classified as either limited or extensive, but the Union for International Cancer Control TNM Classification of Malignant Tumours seventh edition (2009) recommended tumor, node, and metastasis (TNM) staging based on analysis of the International Association for the Study of Lung Cancer (IASLC) database. METHODS: Survival analyses were performed for clinically and pathologically staged patients presenting with SCLC from 1999 through 2010. Prognosis was compared in relation to the TNM seventh edition staging to serve as validation and analyzed in relation to proposed changes to the T descriptors found in the eighth edition. RESULTS: There were 5002 patients: 4848 patients with clinical and 582 with pathological stages. Among these, 428 had both. Survival differences were confirmed for T and N categories and maintained in relation to proposed revisions to T descriptors for seventh edition TNM categories and proposed changes in the eighth edition. There were also survival differences, notably at 12 months, in patients with brain-only single-site metastasis (SSM) compared to SSM at other sites, and SSM without a pleural effusion showed a better prognosis than other patients in the M1b category. CONCLUSION: We confirm the prognostic value of clinical and pathological TNM staging in patients with SCLC, and recommend continued usage for SCLC in relation to proposed changes to T, N, and M descriptors for NSCLC in the eighth edition. However, for M descriptors, it remains uncertain whether survival differences in patients with SSM in the brain simply reflect better treatment options rather than better survival based on anatomic extent of disease.
Authors: N Rodriguez de Dios; P Calvo; M Rico; M Martín; F Couñago; A Sotoca; B Taboada; A Rodríguez Journal: Clin Transl Oncol Date: 2017-04-26 Impact factor: 3.405
Authors: Andrew G Nicholson; Kathleen Torkko; Patrizia Viola; Edwina Duhig; Kim Geisinger; Alain C Borczuk; Kenzo Hiroshima; Ming S Tsao; Arne Warth; Sylvie Lantuejoul; Prudence A Russell; Erik Thunnissen; Alberto Marchevsky; Mari Mino-Kenudson; Mary Beth Beasley; Johan Botling; Sanja Dacic; Yasushi Yatabe; Masayuki Noguchi; William D Travis; Keith Kerr; Fred R Hirsch; Lucian R Chirieac; Ignacio I Wistuba; Andre Moreira; Jin-Haeng Chung; Teh Ying Chou; Lukas Bubendorf; Gang Chen; Giuseppe Pelosi; Claudia Poleri; Frank C Detterbeck; Wilbur A Franklin Journal: J Thorac Oncol Date: 2017-11-07 Impact factor: 15.609
Authors: Joshua K Sabari; Benjamin H Lok; James H Laird; John T Poirier; Charles M Rudin Journal: Nat Rev Clin Oncol Date: 2017-05-23 Impact factor: 66.675